We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Outlook Therapeutics Inc | NASDAQ:OTLK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 1.47% | 8.31 | 8.08 | 8.44 | 8.50 | 8.13 | 8.22 | 120,913 | 01:00:00 |
1. Name and Address of Reporting Person * BioLexis Pte Ltd. | 2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 1/29/2020 | M | 4657852 | A | $0.232 | 21606437 | D (1)(2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Warrant (Right to Buy) | $7.20 (3) | 1/27/2020 | D (4) | 2093750 (3) | (5) | 10/31/2025 | Common Stock | 2093750 | $0.00 (6) | 0 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/27/2020 | A (4) | 2093750 | (5) | 10/31/2025 | Common Stock | 2039750 | $0.00 (6) | 2039750 | D (1)(2) | ||||
Warrant (Right to Buy) | $7.80 (3) | 1/27/2020 | D (7) | 1282051 (3) | (5) | 5/14/2026 | Common Stock | 1282051 | $1.00 (3) | 0 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/27/2020 | A (7) | 1282051 | (5) | 5/14/2026 | Common Stock | 1282051 | $1.00 (3) | 1282051 | D (1)(2) | ||||
Warrant (Right to Buy) | $7.80 (3) | 1/27/2020 | D (8) | 1282051 (3) | (5) | 6/8/2026 | Common Stock | 1282051 | $1.00 (3) | 0 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/27/2020 | A (8) | 1282051 | (5) | 6/8/2026 | Common Stock | 1282051 | $1.00 (3) | 1282051 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/29/2020 | M | 2093750 | (5) | 10/31/2025 | Common Stock | 2093750 | $0.00 (6) | 0 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/29/2020 | M | 1282051 | (5) | 5/14/2026 | Common Stock | 1282051 | $1.00 | 0 | D (1)(2) | ||||
Warrant (Right to Buy) | $0.232 | 1/29/2020 | M | 1282051 | (5) | 6/8/2026 | Common Stock | 1282051 | $1.00 | 0 | D (1)(2) |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
BioLexis Pte Ltd. 36 ROBINSON ROAD #13-01 CITY HOUSE SINGAPORE, U0 068877 | X | X | |||
Pillai Arun Kumar #30, 1ST MAIN J.P. NAGAR 3RD PHASE BANGALORE, K7 560078 | X | X | |||
Sukhtian Ghiath M. 7TH CIRCLE, ZAHRAN STREET ZAHRAN PLAZA BLDG, 4TH FLOOR AMMAN, M2 11844 | X | X |
Signatures | ||
/s/ BioLexis Pte. Ltd., By: Lawrence Kenyon, Attorney-in-Fact | 1/29/2020 | |
**Signature of Reporting Person | Date | |
/s/ Lawrence Kenyon, Attorney-in-Fact | 1/29/2020 | |
**Signature of Reporting Person | Date | |
/s/ Lawrence Kenyon, Attorney-in-Fact | 1/29/2020 | |
**Signature of Reporting Person | Date |
1 Year Outlook Therapeutics Chart |
1 Month Outlook Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions